China's Market Approval Policy and Medical Insurance Payment System for Rare Disease

Published on: Jul 21, 2022

Return to Insights Center

Related Insights

Whitepaper

Overview of China's Market Approval Policy Med Insurance Payment System

Apr 7, 2022

Blog

Advancing rare disease research: Exploring opportunities for Bayesian methods with FDA’s upcoming guidance

Jun 17, 2025

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Blog

Unpacking NICE’s review of the HST routing criteria: implications for manufacturers

Oct 3, 2024

Blog

Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress

May 2, 2024

Playbook

Are you using real-world evidence?

Feb 1, 2023

Blog

Studying rare cancer patient populations using integrated genomic and real-world data

Aug 30, 2023

Blog

Early Scientific Advice in cost effectiveness markets – how to navigate it and is it worth it?

Jun 14, 2023

Blog

Celebrating 40 Years of Rare Disease Progress: WODC Highlights

Jun 6, 2023

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Whitepaper

The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations

Mar 9, 2023

Playbook

Insights from the 2022 R&D Innovation Survey

Feb 17, 2023

Related Insights

Whitepaper

Overview of China's Market Approval Policy Med Insurance Payment System

Apr 7, 2022

Blog

Advancing rare disease research: Exploring opportunities for Bayesian methods with FDA’s upcoming guidance

Jun 17, 2025

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Blog

Unpacking NICE’s review of the HST routing criteria: implications for manufacturers

Oct 3, 2024

Blog

Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress

May 2, 2024

Playbook

Are you using real-world evidence?

Feb 1, 2023

Show more